121 related articles for article (PubMed ID: 35151642)
1. ATRA promotes PD-L1 expression to control gastric cancer immune surveillance.
Ma ZL; Ding YL; Jing J; Du LN; Zhang XY; Liu HM; He PX
Eur J Pharmacol; 2022 Apr; 920():174822. PubMed ID: 35151642
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer.
He PX; Ma ZL; Han H; Zhang XY; Niu SH; Du LN; Zheng YC; Liu HM
Life Sci; 2020 Feb; 242():117247. PubMed ID: 31899223
[TBL] [Abstract][Full Text] [Related]
4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
5. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
6. Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression.
Huang C; Chen B; Wang X; Xu J; Sun L; Wang D; Zhao Y; Zhou C; Gao Q; Wang Q; Chen Z; Wang M; Zhang X; Xu W; Shen B; Zhu W
Gastric Cancer; 2023 Sep; 26(5):691-707. PubMed ID: 37300724
[TBL] [Abstract][Full Text] [Related]
7. PD-L1
Li Q; Zhou ZW; Lu J; Luo H; Wang SN; Peng Y; Deng MS; Song GB; Wang JM; Wei X; Wang D; Westover KD; Xu CX
Mol Ther; 2022 Feb; 30(2):621-631. PubMed ID: 34547468
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma.
Chen XJ; Zhang XQ; Tang MX; Liu Q; Zhou G
Nanomedicine (Lond); 2020 Apr; 15(10):951-968. PubMed ID: 32255397
[No Abstract] [Full Text] [Related]
9. Cancer-Associated Fibroblast-Derived IL-8 Upregulates PD-L1 Expression in Gastric Cancer Through the NF-κB Pathway.
Lou M; Iwatsuki M; Wu X; Zhang W; Matsumoto C; Baba H
Ann Surg Oncol; 2024 May; 31(5):2983-2995. PubMed ID: 38006530
[TBL] [Abstract][Full Text] [Related]
10. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
[TBL] [Abstract][Full Text] [Related]
11. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
Wang H; Zhou Z; Zhang J; Hao T; Wang P; Wu P; Su R; Yang H; Deng G; Chen S; Gu L; He Y; Zeng L; Zhang C; Yin S
Cancer Lett; 2024 Jan; 581():216498. PubMed ID: 38029539
[TBL] [Abstract][Full Text] [Related]
12. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
[TBL] [Abstract][Full Text] [Related]
13. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
14. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.
Shen DD; Pang JR; Bi YP; Zhao LF; Li YR; Zhao LJ; Gao Y; Wang B; Wang N; Wei L; Guo H; Liu HM; Zheng YC
Mol Cancer; 2022 Mar; 21(1):75. PubMed ID: 35296335
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
16. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
17. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis.
Sun L; Wang Q; Chen B; Zhao Y; Shen B; Wang H; Xu J; Zhu M; Zhao X; Xu C; Chen Z; Wang M; Xu W; Zhu W
Cell Death Dis; 2018 Sep; 9(9):928. PubMed ID: 30206229
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
Ju X; Zhang H; Zhou Z; Chen M; Wang Q
Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
[TBL] [Abstract][Full Text] [Related]
19. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
20. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
